Document is current
Any future updates will be listed below
-
Authors
Klein, Hadar
Pachter, Dafna
Goldberg Toren, Dana Tamar
Kamer, Omer
Alufer, Liav
Ebstein Karamani, Noa
Chassidim, Yoash
Shelef, Ilan
Rudich, Assaf
Yoel, Uri
Ben-Arie, Gal
Zelicha, Hila
Yaskolka Meir, Anat
Tsaban, Gal
Bartal, Carmi
Blüher, Matthias
Stumvoll, Michael
Ceglarek, Uta
Isermann, Berend
Qi, Lu
Stampfer, Meir J.
Hu, Frank B.
Shai, Iris
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (Germany’s Excellence Strategy – EXC-3105/1 – 533765739)
- License Information
-
More Information
Article History
Received: 23 August 2025
Accepted: 21 January 2026
First Online: 30 January 2026
Declarations
:
: The Soroka University Medical Centre Medical Ethics Board and the Institutional Review Board approved the study protocols for the CENTRAL (0239-11-SOR) and DIRECT-PLUS (0280-16-SOR) trials, and the FIT follow-up (0373-21-SOR). All participants provided written informed consent and received no financial compensation.
: Not applicable.
: M.B. received honoraria as a consultant and speaker from Amgen, Astra-Zeneca, Bayer, Boehringer Ingelheim, Daiichi-Sankyo, Lilly, Novo Nordisk, Novartis, and Sanofi. All other authors declare that they have no competing interests.
